Our vision is to be the global leader in personalized medical management of gynecologic health to improve clinical outcomes for patients, physicians and payers.
Below you can find stock information, SEC Filings, financial reports, links to webcasts and presentation, and information on the analyst coverage of Vermillion, Inc.
- 2017 Proxy Statement
- VRML 2016 10K
- 2016 Proxy Statement
- 2015 Proxy Statement
- VRML 2015 10K
- VRML 2014 10K
- 2014 Proxy Statement
- 2013 10-K
- 2013 Proxy Statement
- 2012 Proxy Statement Supplement
- 2012 10-K
- VRML 10-K PDF
- Vermillion – 2012 Proxy Statement (Definitive)
- Vermillion Inc. 2010 Annual Report & 2011 Proxy Statement
- Vermillion Inc. 2009 Annual Report and 2010 Proxy Statement
Webcasts and Presentation
LifeSci Advisors Webcast
Gynecologic Key Opinion Leaders on Ovarian Cancer Detection
December 11, 2015 – NY Palace Hotel
Vermillion, Inc. is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Vermillion, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vermillion, Inc. or its management. Vermillion, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
- Canaccord Genuity
- LifeSci Capital